[{"id":"f04191d0-49ef-4557-a5c3-c47df0794683","acronym":"","url":"https://clinicaltrials.gov/study/NCT06782932","created_at":"2025-02-25T19:18:04.732Z","updated_at":"2025-02-25T19:18:04.732Z","phase":"Phase 1/2","brief_title":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","source_id_and_acronym":"NCT06782932","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • balstilimab (AGEN2034) • AGEN2373 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-01-20"},{"id":"0fa8ab04-e7a7-4cdf-a8ec-f0b54cef76dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04121676","created_at":"2022-01-21T18:55:54.943Z","updated_at":"2024-07-02T16:35:12.106Z","phase":"Phase 1","brief_title":"Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer","source_id_and_acronym":"NCT04121676","lead_sponsor":"Agenus Inc.","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e botensilimab (AGEN1181) • AGEN2373"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 09/26/2019","start_date":" 09/26/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-04-01"}]